Efficacy of intravenous immunoglobulin treatment in children with common variable immunodeficiency.

BACKGROUND Children with common variable immunodeficiency (CVID) have increased susceptibility to infections. OBJECTIVE We evaluated the role of intravenous immunoglobulin (IVIG) replacement therapy on the clinical outcome of patients with CVID. METHODS We studied children diagnosed with CVID and treated with IVIG (500 mg/kg every 3 weeks). RESULTS The study population comprised 29 children with CVID (mean [SD] age, 11.8 [6.1] years) with at least 1 year of follow-up before IVIG replacement therapy. Mean follow-up duration was 5.6 (3.5) years (range, 15 months-14 years). During therapy, median serum IgG levels increased from 410 to 900 mg/dL. The mean number of respiratory infections per patient per year decreased significantly from 10.2 to 2.5. The annual number and length of hospital stays decreased significantly from 1.36 to 0.21 and 16.35 to 6.33 days per patient, respectively. The mean annual number of antibiotics used decreased significantly from 8.27 to 2.50 per patient. Twelve patients had developed bronchiectasis before initiation of IVIG; 3 patients were cured of this condition. Age at diagnosis, diagnostic delay, number of respiratory tract infections, and number of antibiotics were found to be significantly higher in patients with bronchiectasis, as was lower B-cell percentage. However, gastrointestinal involvement due to noninfectious causes did not improve significantly after IVIG replacement therapy. CONCLUSION CVID patients treated with IVIG (500 mg/kg every 3 weeks) had satisfactory serum IgG levels, fewer respiratory tract infections, fewer and shorter hospital stays, and reduced antibiotic usage. However, no effect on gastrointestinal involvement was observed. Early IVIG replacement therapy is important in preventing bronchiectasis.

[1]  Kathleen C. Williams,et al.  Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. , 2010, Clinical immunology.

[2]  É. Oksenhendler,et al.  Infections in 252 patients with common variable immunodeficiency. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Toby Lasserson,et al.  Role of physiotherapy in the management of chronic lung diseases: an overview of systematic reviews. , 2007, Respiratory medicine.

[4]  S. Stanworth,et al.  Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review , 2007, Clinical and experimental immunology.

[5]  A. Salavati,et al.  Gastrointestinal Manifestations in Patients with Common Variable Immunodeficiency , 2007, Digestive Diseases and Sciences.

[6]  A. Plebani,et al.  Long-Term Follow-Up and Outcome of a Large Cohort of Patients with Common Variable Immunodeficiency , 2007, Journal of Clinical Immunology.

[7]  J. Orange,et al.  Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. , 2006, The Journal of allergy and clinical immunology.

[8]  E. Dağlı,et al.  Non-Cystic-Fibrosis Bronchiectasis in Children: A Persisting Problem in Developing Countries , 2005, Respiration.

[9]  F. Spertini,et al.  Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non‐respiratory infections in common variable immune deficiency , 2005, Allergy.

[10]  E. Pallisa,et al.  Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. , 2004, International immunopharmacology.

[11]  N. Rezaei,et al.  A review of gastrointestinal disorders in patients with primary antibody immunodeficiencies during a 10-year period (1990-2000), in children hospital medical center. , 2003, Iranian journal of allergy, asthma, and immunology.

[12]  A. Zullo,et al.  Duodenal Pathology and Clinical-Immunological Implications in Common Variable Immunodeficiency Patients , 2003, American Journal of Gastroenterology.

[13]  M. Perpiñá Tordera,et al.  Respiratory disorders in common variable immunodeficiency. , 2001, Respiratory medicine.

[14]  C. Cunningham-Rundles,et al.  Common variable immunodeficiency: clinical and immunological features of 248 patients. , 1999, Clinical immunology.

[15]  D. Redelmeier,et al.  Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency , 1996, Inflammation.

[16]  S. Skull,et al.  Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93. , 1996, Archives of disease in childhood.

[17]  M. Conley,et al.  Retrospective analysis of the incidence of pulmonary disease in hypogammaglobulinemia. , 1991, The Journal of allergy and clinical immunology.

[18]  M. Garbrecht,et al.  Common Variable Immunodeficiency Syndrome and Nodular Lymphoid Hyperplasia in the Small Intestine , 1988, Endoscopy.

[19]  H. Levison,et al.  Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. , 1985, The American journal of medicine.

[20]  B. Pirofsky.  Intravenous immune globulin therapy in hypogammaglobulinemia. A review. , 1984, The American journal of medicine.

[21]  K. Warnatz,et al.  Common variable immunodefi ciency - an update , 2012 .

[22]  A. Eifan,et al.  Clinical and immunologic features of pediatric patients with common variable immunodeficiency and respiratory complications. , 2008, Journal of investigational allergology & clinical immunology.

[23]  B. Piqueras,et al.  Common Variable Immunodeficiency Patient Classification Based on Impaired B Cell Memory Differentiation Correlates with Clinical Aspects , 2003, Journal of Clinical Immunology.

[24]  C. Kallenberg,et al.  The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. , 2001, Annals of internal medicine.

[25]  L. Notarangelo,et al.  Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). , 1999, Clinical immunology.